- Home
- ISPO vs ESLA Comparison
ISPO vs ESLA Comparison
Compare ISPO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPO
- ESLA
- Stock Information
- Founded
- ISPO 2010
- ESLA 2021
- Country
- ISPO United States
- ESLA United States
- Employees
- ISPO N/A
- ESLA N/A
- Industry
- ISPO Blank Checks
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISPO Finance
- ESLA Health Care
- Exchange
- ISPO Nasdaq
- ESLA Nasdaq
- Market Cap
- ISPO 39.0M
- ESLA 41.6M
- IPO Year
- ISPO N/A
- ESLA N/A
- Fundamental
- Price
- ISPO $6.99
- ESLA $1.18
- Analyst Decision
- ISPO Buy
- ESLA
- Analyst Count
- ISPO 2
- ESLA 0
- Target Price
- ISPO $10.50
- ESLA N/A
- AVG Volume (30 Days)
- ISPO 71.9K
- ESLA 17.0K
- Earning Date
- ISPO 03-04-2025
- ESLA 02-12-2025
- Dividend Yield
- ISPO N/A
- ESLA N/A
- EPS Growth
- ISPO N/A
- ESLA N/A
- EPS
- ISPO N/A
- ESLA N/A
- Revenue
- ISPO $287,451,000.00
- ESLA N/A
- Revenue This Year
- ISPO N/A
- ESLA N/A
- Revenue Next Year
- ISPO N/A
- ESLA N/A
- P/E Ratio
- ISPO N/A
- ESLA N/A
- Revenue Growth
- ISPO N/A
- ESLA N/A
- 52 Week Low
- ISPO $3.11
- ESLA $0.63
- 52 Week High
- ISPO $9.31
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- ISPO 87.48
- ESLA 51.64
- Support Level
- ISPO $3.26
- ESLA $1.05
- Resistance Level
- ISPO $3.75
- ESLA $1.27
- Average True Range (ATR)
- ISPO 0.49
- ESLA 0.15
- MACD
- ISPO 0.31
- ESLA -0.01
- Stochastic Oscillator
- ISPO 95.40
- ESLA 53.33
About ISPO Inspirato Incorporated
Inspirato Inc is a luxury travel subscription luxury travel company that provides exclusive access to a managed and controlled portfolio of curated vacation options, delivered through a model designed to ensure the service, certainty, and value that discerning customers demand. The Inspirato portfolio includes branded luxury vacation homes, accommodations at five-star hotel and resort partners, and custom travel experiences. It has a geographic location in the United States and Outside the United States. It generates the majority of its revenue from the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.